A Bayesian approach for individual-level drug benefit-risk assessment.


In existing benefit-risk assessment (BRA) methods, benefit and risk criteria are usually identified and defined separately based on aggregated clinical data and therefore ignore the individual-level differences as well as the association among the criteria. We proposed a Bayesian multicriteria decision-making method for BRA of drugs using individual-level data. We used a multidimensional latent trait model to account for the heterogeneity of treatment effects with latent variables introducing the dependencies among outcomes. We then applied the stochastic multicriteria acceptability analysis approach for BRA incorporating imprecise and heterogeneous patient preference information. We adopted an efficient Markov chain Monte Carlo algorithm when implementing the proposed method. We applied our method to a case study to illustrate how individual-level benefit-risk profiles could inform decision-making.





Published Version (Please cite this version)


Publication Info

Li, Kan, Sheng Luo, Sammy Yuan and Shahrul Mt-Isa (2019). A Bayesian approach for individual-level drug benefit-risk assessment. Statistics in medicine, 38(16). pp. 3040–3052. 10.1002/sim.8166 Retrieved from https://hdl.handle.net/10161/19136.

This is constructed from limited available data and may be imprecise. To cite this article, please review & use the official citation provided by the journal.



Sheng Luo

Professor of Biostatistics & Bioinformatics

Unless otherwise indicated, scholarly articles published by Duke faculty members are made available here with a CC-BY-NC (Creative Commons Attribution Non-Commercial) license, as enabled by the Duke Open Access Policy. If you wish to use the materials in ways not already permitted under CC-BY-NC, please consult the copyright owner. Other materials are made available here through the author’s grant of a non-exclusive license to make their work openly accessible.